Retinal Surgery

As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

An end-of-week review of retina news and stories from October 29-November 3, 2022.

The investigators suggested that the predicted metastasis-free survival for metastatic tumors may be worse than what they and other research groups have observed.

A combination of posters, podium presentations, and instructional courses provided invaluable revelations to the ophthalmic community.

The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.

Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

How long-term intravitreal steroid technology fits into a modern clinic.

A synopsis of the findings presented at EURETINA 2022 for ophthalmologists and retina specialists.

European investigators describe how they address complications associated with silicone oil endotamponade in vitreoretinal surgery.

The contest will take place as part of World Retina Day, Saturday, September 3, from 8:30-9:30 CEST in Hall X2/Channel 7.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

The effects of cataract surgery are generally evaluated based on improvements in vision, but investigators sought to identify if the structures in the back of the eye were affected as well.

At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”

At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.

The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, from July 13-16, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular edema dominated the conversation.

J. Fernando Arevalo, MD, PhD, investigated the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the two, and suggested that the combination approach may need further consideration.

At ASRS 2022 in New York City, New York, Rishi Singh, MD, is presenting, “12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial.” The Phase 1 trial showed a reduction in treatment burden over 12 months as well as a favorable safety profile.

Rhegmatogenous detachments increased with age; myopia, trauma, and history of retinopathy were common underlying risk factors for development of rhegmatogenous retinal detachments.

Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.

CAM encourages corneal healing in patients with ocular surface disease.

A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.

The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York.

A study by Orbis International found that children with myopia experienced significantly higher levels of depression and anxiety than their peers without vision impairment.

Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.

Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.

Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.